Exact Sciences marked a 1.1% change today, compared to 0.0% for the S&P 500. Is it a good value at today's price of $60.13? Only an in-depth analysis can answer that question, but here are some facts that can give you an idea:
-
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally.
-
Exact Sciences belongs to the Health Care sector, which has an average price to earnings (P/E) ratio of 30.21 and an average price to book (P/B) of 4.08
-
The company's P/B ratio is 3.48
-
Exact Sciences has a trailing 12 month Price to Earnings (P/E) ratio of -38.1 based on its trailing 12 month price to earnings (EPS) of $-1.58 per share
-
Its forward P/E ratio is -60.7, based on its forward earnings per share (EPS) of $-0.99
-
EXAS has a Price to Earnings Growth (PEG) ratio of -0.46, which shows the company has a fair value when we factor growth into the price to earnings calculus.
-
Over the last four years, Exact Sciences has averaged free cash flows of $-188583000.0, which on average grew 37.7%
-
Exact Sciences has moved -10.1% over the last year compared to 19.4% for the S&P 500 -- a difference of -29.5%
-
EXAS has an average analyst rating of buy and is -34.33% away from its mean target price of $91.56 per share